Scientists have developed a new mRNA vaccine to treat pancreatic cancer that may extend patients' lifespans by 8 to 10 years.

Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. Find out why I rate CADL stock ...

On Tuesday, the European Commission (EC) conditionally approved Merck & Co Inc’s (NYSE:MRK) Welireg (belzutifan), an oral ...

Genprex, Inc. ("Genprex" or the "Company") , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the advancement ...

Merck (MRK) announced that the European Commission has conditionally approved WELIREG, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, ...

Rezolute advances therapies for hypoglycemia with RZ358 and RZ402, showing efficacy in trials. Read why RZLT stock is a compelling, albeit cautious, investment.

Liver issues, including a buildup of fat in the liver, occur before the onset of neuromuscular disease, per a study in a ...

The expanded study will now examine the combination of Alpha DaRT and chemotherapy in patients with newly diagnosed metastatic pancreatic cancer, along with those with locally advanced disease.

Defective alpha cell secretory responses to glucose and paracrine effectors in both Type 1 and Type 2 diabetes may drive the development of hyperglucagonemia. Therefore, uncovering the mechanisms that ...

Objective Pancreatic ductal adenocarcinoma (PDAC ... and converted CAFs into myoCAFs, which hijacked low metastatic cancer cells for metastasis. The interleukin (IL)-33–ST2–TAMs axis was the primary ...

A subset of samples (n=20) and blanks (n=5) were spiked with known concentrations of bacterial cells alien to the human microbiome to infer absolute abundances ... Conclusion The ‘microbiome’ of IPMNs ...